Sponsor content

Focusing on synaptic protection in Alzheimer’s

Cognition Therapeutics, Inc. has a first-in-class, clinical-stage, highly brain-penetrant and orally bioavailable small molecule designed to halt the initiation and progression of Alzheimer’s disease.

Go to the profile of Cognition Therapeutics
Oct 26, 2016
Upvote 1 Comment
Page of
Go to the profile of Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer’s disease and other neuro- degenerative diseases of the human brain.

No comments yet.